Literature DB >> 29218818

Loss of fundus view as an indication for secondary enucleation in retinoblastoma.

Jesse L Berry1,2, Kaitlin Kogachi1,2, Rima Jubran3, Jonathan W Kim1,2.   

Abstract

In this retrospective study, we evaluated loss of fundus view as an indication for secondary enucleation and associated histopathologic findings. Of 64 secondarily enucleated eyes, 24 were enucleated for loss of fundus view. Average time from loss of fundus view to enucleation was 4.7 months. Of these eyes, 22 had viable tumor cells on histopathology, but none had high-risk features. Loss of fundus view was a common indication for secondary enucleation after chemoreduction. Given the high prevalence of viable histopathologic tumor cells, enucleation for loss of fundus view should not be significantly delayed to decrease risk of high-risk tumor progression.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  high-risk histopathology; loss of fundus view; retinoblastoma; secondary enucleation

Mesh:

Year:  2017        PMID: 29218818      PMCID: PMC7446180          DOI: 10.1002/pbc.26908

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  9 in total

1.  Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis.

Authors:  Junyang Zhao; Helen Dimaras; Christine Massey; Xiaolin Xu; Dongsheng Huang; Bin Li; Helen S L Chan; Brenda L Gallie
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

Review 2.  Intraocular retinoblastoma: the case for a new group classification.

Authors:  A Linn Murphree
Journal:  Ophthalmol Clin North Am       Date:  2005-03

Review 3.  Treatment of Retinoblastoma in 2015: Agreement and Disagreement.

Authors:  David H Abramson; Carol L Shields; Francis L Munier; Guillermo L Chantada
Journal:  JAMA Ophthalmol       Date:  2015-11       Impact factor: 7.389

4.  Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.

Authors:  Jesse L Berry; Rima Jubran; Jonathan W Kim; Kenneth Wong; Simon R Bababeygy; Hashem Almarzouki; Thomas C Lee; A Linn Murphree
Journal:  Pediatr Blood Cancer       Date:  2012-09-19       Impact factor: 3.167

5.  Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.

Authors:  Carol L Shields; Santosh G Honavar; Anna T Meadows; Jerry A Shields; Hakan Demirci; Arun Singh; Debra L Friedman; Thomas John Naduvilath
Journal:  Am J Ophthalmol       Date:  2002-05       Impact factor: 5.258

6.  Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation.

Authors:  Jesse L Berry; Kaitlin Kogachi; Hassan A Aziz; Kathleen McGovern; Emily Zolfaghari; A Linn Murphree; Rima Jubran; Jonathan W Kim
Journal:  Pediatr Blood Cancer       Date:  2016-11-05       Impact factor: 3.167

7.  High-Risk Histopathology Features in Primary and Secondary Enucleated International Intraocular Retinoblastoma Classification Group D Eyes.

Authors:  Ido D Fabian; Andrew W Stacey; Tanzina Chowdhury; Catriona Duncan; Esin K Karaa; Irene Scheimberg; M Ashwin Reddy; Mandeep S Sagoo
Journal:  Ophthalmology       Date:  2017-03-13       Impact factor: 12.079

8.  Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.

Authors:  Kaan Gündüz; Ilhan Günalp; Nilüfer Yalçindağ; Emel Unal; Nurdan Taçyildiz; Esra Erden; Pinar Ozdemir Geyik
Journal:  Ophthalmology       Date:  2004-10       Impact factor: 12.079

9.  Predictive factors of invasion in eyes with retinoblastoma enucleated after eye salvage treatments.

Authors:  Julia Balaguer; Matthew W Wilson; Catherine A Billups; John Mancini; Barrett G Haik; Ibrahim Qaddoumi; Joseph D Khoury; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

  9 in total
  2 in total

1.  Posterior Vitreous Detachment and the Associated Risk of Retinal Toxicity with Intravitreal Melphalan Treatment for Retinoblastoma.

Authors:  Jesse L Berry; Ramon Lee; Luv Patel; Bao Han A Le; John O'Fee; Rima Jubran; Jonathan W Kim
Journal:  Ocul Oncol Pathol       Date:  2018-11-02

2.  Intra-Arterial Chemotherapy as Primary Treatment for Advanced Unilateral Retinoblastoma in China.

Authors:  Tingyi Liang; Xin Zhang; Jiakai Li; Xuming Hua; Peiquan Zhao; Xunda Ji
Journal:  Front Med (Lausanne)       Date:  2022-04-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.